Skip to Main Content

An official website of the United States government

Government Funding Lapse

Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted. The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit  cc.nih.gov. Updates regarding government operating status and resumption of normal operations can be found at OPM.gov.

DRE and prostate cancer detection in the PLCO cancer screening trial

Principal Investigator
Name
Jonathan Shoag
Degrees
MD
Institution
NA
Position Title
Resident Physician
Email
About this CDAS Project
Study
PLCO (Learn more about this study)
Project ID
PLCO-150
Initial CDAS Request Approval
Aug 24, 2015
Title
DRE and prostate cancer detection in the PLCO cancer screening trial
Summary
Prostate cancer screening within the PLCO trial involves two primary components, prostate specific antigen (PSA) screening and digital rectal exam (DRE). While much of the discussion regarding prostate cancer screening, both within the trial and throughout the urologic literature, has focused on PSA, there is little discussion regarding the role of DRE in screening. With the most recent United States Preventative Services Task Force (USPSTF) guidelines recommending against PSA screening, DRE has become even more crucial to the detection of prostate cancer.
We will compare patients within the screening arm who were found to have an abnormal DRE with those who were found to have an abnormal PSA.
Aims

1. We intend to compare the sensitivity of PSA and DRE for the overall detection of prostate cancer and, more specifically, high grade prostate cancer.
2. To compare the mortality outcomes of patients with prostate cancer initially detected on DRE vs PSA or both.

Collaborators

Xiangmei Gu (statistician, no institution)

Related Publications